ERBB2 and neoplasm: Specifically, in HER2/neu or Wnt1 tumor models we find that lineage-marked residual tumor cells surviving oncogenic pathway inhibition exhibit cellular dormancy, retain the ability to re-enter the cell cycle after extended periods of quiescence, and express markers shared with mammary stem cells as well as tumor-initiating cells.